Back

A Small-molecule Antagonist Radiotracer for Positron Emission Tomography Imaging of the Mu Opioid Receptor.

Plakas, K.; Hsieh, C.-J.; Guarino, D. S.; Hou, C.; Chia, W.-K.; Young, A.; Schmitz, A.; Ho, Y.-P.; Weng, C.-C.; Lee, H.; Li, S.; Graham, T. J. A.; Mach, R. H.

2024-10-12 neuroscience
10.1101/2024.10.12.618019 bioRxiv
Show abstract

The opioid crisis is a catastrophic health emergency catalyzed by the misuse of opioids that target and activate the mu opioid receptor. Traditional radioligands used to study the mu opioid receptor are often tightly regulated owing to their abuse and respiratory depression potential. In the present study, we sought to design and characterize a library of 24 non-agonist ligands for the mu opioid receptor. Ligands were evaluated for the binding affinity, intrinsic activity, and predicted blood-brain barrier permeability. Several ligands demonstrated single-digit nM binding affinity for the mu opioid receptor while also demonstrating selectivity over the delta and kappa opioid receptors. The antagonist behavior of 1A and 3A at the mu opioid receptor indicate that these ligands would likely not induce opioid-dependent respiratory depression. Therefore, these ligands can enable a safer means to interrogate the endogenous opioid system. Based on binding affinity, selectivity, and potential off-target binding, [11C]1A was prepared via metallophotoredox of the aryl-bromide functional group to [11C]methyl iodide. The nascent radiotracer demonstrated brain uptake in a rhesus macaque model and accumulation in the caudate and putamen. Naloxone was able to reduce [11C]1A binding, though the interactions were not as pronounced as naloxones ability to displace [11C]carfentanil. These results suggest that GSK1521498 and related congeners are amenable to radioligand design and can offer a safer way to query opioid neurobiology.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
ACS Chemical Neuroscience
60 papers in training set
Top 0.1%
19.4%
2
European Journal of Medicinal Chemistry
16 papers in training set
Top 0.1%
10.9%
3
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.1%
6.6%
4
Scientific Reports
3102 papers in training set
Top 15%
6.6%
5
International Journal of Molecular Sciences
453 papers in training set
Top 2%
3.8%
6
Journal of Medicinal Chemistry
68 papers in training set
Top 0.3%
3.7%
50% of probability mass above
7
PLOS ONE
4510 papers in training set
Top 47%
2.2%
8
eLife
5422 papers in training set
Top 37%
2.0%
9
NeuroImage
813 papers in training set
Top 4%
1.9%
10
Brain Research
35 papers in training set
Top 0.7%
1.8%
11
Chemical Communications
24 papers in training set
Top 0.4%
1.8%
12
Pharmacology Research & Perspectives
11 papers in training set
Top 0.1%
1.5%
13
RSC Advances
18 papers in training set
Top 0.7%
1.4%
14
Neurotherapeutics
11 papers in training set
Top 0.2%
1.4%
15
European Journal of Nuclear Medicine and Molecular Imaging
19 papers in training set
Top 0.2%
1.4%
16
Pharmacological Research
15 papers in training set
Top 0.1%
1.3%
17
Molecules
37 papers in training set
Top 1%
1.3%
18
Theranostics
33 papers in training set
Top 0.9%
1.2%
19
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.5%
1.0%
20
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.3%
0.8%
21
ACS Omega
90 papers in training set
Top 4%
0.8%
22
Bioorganic & Medicinal Chemistry Letters
10 papers in training set
Top 0.3%
0.8%
23
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.8%
24
JACS Au
35 papers in training set
Top 1.0%
0.8%
25
Neuropsychopharmacology
134 papers in training set
Top 2%
0.8%
26
Communications Biology
886 papers in training set
Top 24%
0.7%
27
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.7%
28
Advanced Science
249 papers in training set
Top 19%
0.7%
29
Journal of Psychopharmacology
14 papers in training set
Top 0.7%
0.7%
30
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.7%